patients receiving neuroleptic medication plus the antiparkinsonian drug, benztropine mesylate, were either switched to placebo or maintained on benztropine. Patients withdrawn from benztropine reliably increased their overall scoreson theWechslerMemory Scaleincomparisonwiththedrug group. Sub-test scores suggest that deficits inattention andconcentration were induced by treatment with benztropine. Psychotic decompensation appeared to develop simultaneously with extrapyramidal symptoms (EPS) in some patients, butonly14.2percentoftheplacebogroupexperienced extrapyra midalsymptoms severe enoughtorequire resumption ofbenztropine therapy. It is suggested that antiparkinsonian agents should be prescribed only if and when EPSoccur.
Controversy has arisen about the use of anti parkinsonian agents such as benztropine mesylate (â€˜Cogentin'). Pecknold et al (1971) maintained that antiparkinsonian agents are frequently prescribed when not required, and argued that â€oe¿ the occurrence of extrapyramidal symptoms is often a transient manifes tation,. . . followed by spontaneous disappearance.â€• The effectiveness of antiparkinsonian medication for drug-induced EPS, even when needed, has also been questioned (Mindham Ct al, 1972; Chien, DiMascio, and Cole, 1974; Swett et al, 1977) . For these reasons, the wisdom of using combined antipsychotic and antiparkinsonian therapy over extended time periods isdebatable.
Despite the widespread use of benztropine, remark ably few controlled investigations evaluating its rela tive merits and drawbacks have been reported. In particular, although a number of reports have com mented on the toxic confusional state occasionally induced by excessive or even therapeutic amounts of the drug (e.g. Dunlap and Miller, 1969; Ananth and Jam, 1973) , little attention has been paid to more subtle cognitive impairment associated with commonly prescribed dosages (ito 2mg, with a range of.S to 6mg daily). The present investigation was designed to examine the effects of the withdrawal of sub-confu sional doses of benztropine on cognitive and emotional functioning, psychiatric state, and general ward behav iour, as well as on EPS.
Method

Subjects
Twenty-eight schizophrenic patients (14 in-patients and 14 out-patients) from Kingston Psychiatric Hospi tal, who had received a combination of benztropine mesylate and antipsychotic medication for at least three months were included in the study. Carpenter's flexible system for the diagnosis of schizophrenia (Carpenter, 1973) was used to confirm the diagnoses.
Other criteria for the selection of subjects included a verbal intelligence score of at least 70 (determined by prorating test scores on the WAIS Vocabulary sub test) and the absence of alcoholism, epilepsy, brain damage, or neurological disorder such as idiopathic parkinsonism. Those receiving antidepressant or anti convulsant medication, or those given ECT within the previous six weeks, were also excluded.
The patient sample consisted of 16 males and 12 females, ranging in age from 18 to 48, with a mean age of 30. Forty per cent of the patients were being treated with a single antipsychotic agent, while the remainder were receiving a combination of two antipsychotic drugs. The most frequently used drug was flu phenazine enanthate (11 patients), followed by trifluoperazine (eight patients), thioridazine (six patients), fluphenazine decanoate and chlorpromazine (four patients each), and pimozide (three patients). Perphenazine, mesoridazine, haloperidol, and loxa pine were given to only one patient each. (Aquilonius, 1978; Snyder, Greenberg and Yamamura, 1974) . Members of each matched-pair were then assigned randomly to either a drug or placebo group. Mean values for the matched characteristics for-each patient group are summarized inTablel.
Both placebo and active benztropine drug were administered double-blind in identical capsules, with a two-week adaptation period to accustom patients to taking antiparkinsonian medication in this new form. ike-study dosage schedules were maintained, and no changes in neuroleptic medication were permitted during the course of the study.
At the conclusion Ã¡fthe adaptation period, ratings @f ward behaviour, mental status, and affective state were made using the Nurses' Observation Scale of In patient Evaluation (NOSIE-30) (Homgfeld, Gillis, and Klett, 1966) , the Brief Psychiatric Rating Scale (BPRS) (Overall and Gorham, 1962) , the state form of the State-Trait Anxiety Inventory (STAI) (Spielberger, Gorsuch, and Lushene, 1970) , and the Beck Depression Inventory (BDI) (Beck et a!, 1961 (Simpson and Angus, 1970) and the Autonomic Symptoms Scale (Mindham eta!, 1972) . On the day following testing, half of the patients were started on placebo and the other half maintained on the active benztropine. Two weeks later, all measurements except â€˜¿ those involving memory and attention were repeated. The complete set of tests and ratings was readministered four weeks after the initial assessments. (Klett and Caffey, 1972 , have stated that patients needing to continue antiparkinsonian medica tion usually develop EPS within 2â€"4weeks after withdrawal). Testing was scheduled for 1â€"1/2hours after ingestion of a 2 mg dose of benztropine or placebo, and place and time of day for testing were kept constant for each subject.
If extrapyramidal symptoms or psychiatric decom pensation severe enough to require the read ministration of benztropine developed in any members of the placebo group, they were retested as soon as possible, along with their matched partners, before the resumption of antiparkinsonian medication or change of neuroleptics.
Results and Discussion
All test-score data were analysed using a two-factor (drug vs. placebo, in-patient vs. out-patient) , com pletely randomised analysis of variance applied to the difference scores between test sessions.
Psychological tests
The most notable result of this investigation was the would appear to be attributable, therefore, to im proved attention and concentration rather than mem ory, although the mechanisms of memory and attention are admittedly difficult to disentangle. Despite the fact that atropinic drugs have long been known to produce an amnestic syndrome, the relation ship between benztropine and subtle cognitive impair ment at sub-confusional dosages has not previously been subject to controlled investigation. Previous reports of impaired memory, attention, and orienta tion associated with a toxic confusional state have consisted largely of either anecdotal evidence or of uncontrolled observations (e.g. Davies et a!, 1971; El Yousef et a!, 1972) . In these reports, other drugs were administered concomitantly with the benztropine, so that it is unclear whether the effects on memory are attributable to the benztropine, the other drugs, or to some combination thereof. Moreover, the nature of the particular cognitive deficits was not firmly established.
Further information about the specific nature of the cognitive deficits likely to be associated with benztropine therapy must therefore be inferred from the results of investigations of similar anticholinergic compounds such as atropine, scopolamine, and other antiparkinsonian agents. These studies, which are considerably better controlled than the case reports involving benztropine described above, indicate that short-term rather than immediate or long-term mem ory, and the ability to sustain rather than focus attention, are most likely to be affected. For example, no noticeable effect on the recall of digits forwards or backwards (immediate memory) was noted after scopolamine (Drachman and Leavitt, 1974) , after higher as opposed to lower doses of scopolamine (Ostfeld and Aruguete, 1962) , or after benzhexol hydrochloride (Potamianos and Kellett, 1982) , al though Safer and Allen (1971) reported mild impair ment after scopolamine. However, these drugs did cause decrements in performance on tests measuring the ability to recall objects and words after a short delay (Card Object Recall, Logical Memory and Associate Learning subtests of the WMS) and to maintain an attentive set (Buzzer Press) (Ostfeld and Aruguete, 1962) ; to recall digits after a delay (20-sec delayed recall of digits) (Safer and Allen, 1971) ; to store new information (Supraspan Digit Storage and Free Recall Word Storage), and to retrieve informa LINDA A. BAKER, L. Y. CHENG AND I. B. AMARA tion from long-term memory (Retrieval by Category Test); (Drachman and Leavitt, 1974) ; and to learn new material and recall it after a short delay (Word List, Short Story, and New Word Learning Tests) (Potamianos and Kellett, 1982) .
Thus, it would appear that cognitive impairment attributable to benztropine may be of a different and more elemental type than that caused by other atropinic compounds.
The cholinergic pharmaco system, which is known to include the limbic system, has been particularly implicated in learning and memory. Since the ascending reticular activating system is also considered one of the major cholinergic systems in the brain, it may be that the drug-induced deficits in immediate memory (which is primarily an attentional stage) suggested by this study are attribut able to a state of under-arousal created by the effect of benztropine on this system. It is also possible that the impairment of immediate memory and attention that was observed is related to the nature of the patient sample. In other studies, it has been noted that distractibility is a feature of schizophrenia (McGhie, Chapman, and Lawson, 1965; Blum, Livingston, and Shader, 1969) and that these attentional deficits are responsive to treatment with neuroleptics (Spohn et al, 1978; Oltmanns, Ohayon, and Neale, 1978) . Perhaps benztropine antagonises the effects of neuroleptic medication in alleviating this attentional deficit, in which case the improvement in the placebo group on tests measuring attention and concentration could be related to the removal of this anti-therapeutic influence.
Further evidence for the role of central cholinergic mechanisms in memory function comes from studies involving physostigmine salicylate, a reversible anti cholinesterase agent that crosses the blood-brain barrier and increases brain acetylcholine levels. As Duvoisin and Katz (1968) have stated, â€oe¿ the mutual antagonism of atropine and physostigmine has long been employed in physiology as an indicator of cholinergic function.â€• Physostigmine has frequently been used to reverse the toxic confusional state (also referred to as the â€oe¿ central anticholinergic syndromeâ€•) brought about by drugs with anticholinergic properties (Forrer and Miller, 1958; Duvoisin and Katz, 1968; Granacher and Baldessarini, 1975; Aquilonius, 1978) .
A few controlled studies have also investigated the ability of physostigmine to reverse the effects of anticholinergic drugs on cognitive function. El-Yousef et al (1973) found that disorientation and short-term memory loss (inability to remember three two-digit numbers given 30 seconds previously), which devel oped after use of a combination of benztropine and phenothiazines, were reversed by physostigmine, and Drachman (1977) reported that scopolamine-induced impairment on tests of memory storage was also alleviated. In a study of the effects of lithium and physostigmine on cognitive function, Telford and Worrall (1978) observed that performance on four WAIS subtests (Comprehension, Vocabulary, Block
Design, and Object Assembly) remained the same while on or offlithium, but was enhanced after lithium plus physostigmine.
Psychiatric observations and tests
Three placebo patients developed problems acute enough to warrant early withdrawal from the study all within the first two weeks after medication was discontinued. One patient became overtly psychotic, whereas the other two developed EPS: thus, 14.2 per cent (two of the 14) of the placebo group developed EPS severe enough to warrant resumption of the medication, well within the rate of 30 per cent or less that, with a few exceptions, has been reported in the literature (e.g. DiMascio and Demirgian, 1970; Pecknold et a!, 1971; Klett and Caffey, 1972) . Interestingly, both of the patients developing EPS presented evidence of concomitant psychotic decom pensation. In one case, the patient incorporated his physical symptoms into his delusional system, stating that a disc jockey in a nearby town was using radio waves to cause his rigidity, oculogyric crises, and tachycardia. The simultaneous development of both EPS and psychiatric deterioration in response to antiparkinsonian drug withdrawal has been noted several times in recent literature. Caroli et al (1975) recorded acute psychotic outbreaks among more than a third of the patients withdrawn from antipark insonian medication in their study. In a more carefully controlled investigation, Manos, Gkiouzepas, and Logothetis (1981) noted that 22.6 per cent of a group maintained on trihexyphenidyl suffered psychotic outbreaks related primarily to the withdrawal of antiparkinsonian medication. The psychotic flare-ups included delusions, hallucinations, aggression or vio lence, suicide attempts, withdrawal from work, and isolation, which the authors relate directly to symp toms of rigidity, restlessness, akathisia, and akinesia. Manos (1981) stresses that the psychotic symptoms were â€oe¿ not related to the previous psychotic picture but were the subjective experience or objective mani festation of disturbing extrapyramidal symptomato logy.â€ •Van Kammen (1981) has postulated that the removal of antiparkinsonian drugs may lead to an increase in neuroleptic blood levels in some patients beyond a therapeutic level. Alternatively, we have suggested elsewhere (Cheng, Baker, and Amara, 1981) that the withdrawal of an anticholinergic agent may disturb a previously established cholinergic dopaminergic balance, thus triggering a relapse.
THEWITHDRAWAL OFBENZTROPINE MESYLATE IN CHRONIC SCHIZOPHRENIC PATIENTS
Five other placebo patients (36 per cent) developed EPS during the course of the study, but these were not severe enough to necessitate withdrawal from the investigation. The seven patients in all who developed some form of EPS showed little difference when compared with the total group, except that the average age (28) was slightly lower, the mean amount of benztropine prescribed (4.3 mg/day) was almost 1 mg/ day higher, and they were more likely to be treated with low-dose high-potency drugs such as fluphenazine, trifluoperazine, and pimozide that are low in anticholinergic effect.
Seven (i.e. half) of the placebo patients complained of vomiting, nausea, or flu-like symptoms within the first couple ofweeks ofCogentin withdrawal, the cause of which may have been a cholinergic rebound, resulting from the abrupt removal of the parasympa thetic effects of anticholinergic medication (Kalman and Warner, 1978) . Only a few reports of such reactions after the abrupt discontinuation of anti cholinergic medication have been noted (Innes and Nickerson, 1975; Kalman and Warner, 1978) , but because of the frequency with which this adverse reaction was noted in the present study, it appears that sudden withdrawal of antiparkinsonian drugs should be avoided whenever possible. Some positive comments were also received about certain of the patients withdrawn from Cogentin. These patients, who were described by medical staff as becoming more mentally alert, had the highest antimuscarinic potency scores of the placebo group, indicating that the anticholinergic potency of their medications (before Cogentin was discontinued) had been higher than for the other patients.
No statistically significant results were observed for the tests assessing change in psychiatric state (NOSIE and BPRS), except for the Interest sub-scale of the NOSIE, two weeks after withdrawal [F(1,12) = 5.11, P <.05]. The lack of reliable results, coupled with the obvious clinical deterioration of some of the patients, would seem to contradict the claim of Singh and his colleagues that benztropine reverses the therapeutic effects of neuroleptic medication. Their initial study (Singh and Smith, 1973) was not performed blind, however, and there was no placebo control. In their two further studies (Singh and Kay, 1974; , benztropine was not administered at full-strength for more than two weeks at a time; therefore, they do not really answer the question as to whether the non therapeutic changes observed with benztropine are persistent. The cognitive disturbances noted in the present study may have been a more long-term effect of Cogentin, and the absence of any other anti therapeutic effect is more in line with evidence reviewed by Ziemba, Meltzer, and Davis (1978) group. This result is difficult to interpret, and we can only suggest that the use ofself-rating scales is not to be recommended in future investigations, as it is unrea sonable to expect reliable data from a population of chronic schizophrenics.
Conclusions
Our results indicate that the antiparkinsonian drug Cogentin may have previously unnoted effects on attention and concentration, even at clinically ac cepted dosage levels. None of the tests evaluating EPS indicated that placebo patients became reliably worse, and only two of the 14 patients in this group experienced recrudescence of EPS severe enough to require resumption of benztropine therapy. This result, taken together with the adverse effects documented on attention and concentration, as well as the possibility of developing unpleasant peripheral anticholinergic side-effects such as blurred vision, dry mouth, and constipation, suggests that antiparkin sonian agents are probably over-utilized, and should be prescribed only if and when EPS appear. Further more, this medication should be discontinued gradu ally after a limited period of time (three months should be sufficient) and the patient re-evaluated. Patients maintained on the drug should be kept under constant scrutiny. The prescription of benztropine should therefore be made with caution, and the need for its continuation frequently reassessed.
